Oncology

Cancer control in a time of crisis - the pharmaphorum podcas...

During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with

News

Geron finally gets close to a product approval with imetelst...

More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic

News

CStone gets a win for sugemalimab in oesophageal cancer

Suzhou-based CStone Pharmaceuticals' checkpoint inhibitor sugemalimab has proved effective in a trial as a first-line therapy for oesophageal cancer, setting up a regulatory filing in China

Digital

A few of 2022’s biggest pharma trends – the pharmaphorum pod...

As we close out the year, pharmaphorum's editorial team sat down together for a roundtable discussion of some of the biggest trends they tracked this year in the world of

News

Gilead grabs full rights to Jounce cancer immunotherapy

Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th

Oncology

After a slow start for expensive CAR-T therapies, drug devel...

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o

Cancer control in a time of crisis - the pharmaphorum podcas...

Geron finally gets close to a product approval with imetelst...

CStone gets a win for sugemalimab in oesophageal cancer

A few of 2022’s biggest pharma trends – the pharmaphorum pod...

Gilead grabs full rights to Jounce cancer immunotherapy

After a slow start for expensive CAR-T therapies, drug devel...

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

Oncology

Editor's Picks